ReviewFrontiers in pharmacology2025
Research progress on the mechanisms of polysaccharides derived from traditional Chinese medicine in the treatment of Parkinson's disease.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neuroprotective Effects of Cistanoside A against Cadmium-induced Neurotoxicity via Keap1/Nrf2/NF-kB Signaling: In Vivo and In Silico approaches.Molecular neurobiology · 2026Article
- Review
- Stigmasterol exerts antioxidant effects through activation of the Keap1/Nrf2 signaling pathway in Parkinson's disease model.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is currently a highly prevalent neurodegenerative disease. Its pathogenesis is complex, and there is no effective method to prevent the disease progression. Traditional Chinese medicine (TCM) has a unique advantage in treating PD through the approach of syndrome differentiation. TCM prescriptions for PD can reduce Unified Parkinson's Disease Rating Scale (UPDRS) scores, improve non-motor symptoms, and decrease adverse drug reactions. Bioactive polysaccharides extracted from prescribed Chinese herbs exhibit diverse biological activities due to their wide range of botanical sources. This review summarizes the pharmacological mechanisms of polysaccharides derived from TCM in managing PD, including inhibition of apoptosis, activation of autophagy, regulation of inflammation, anti-oxidative stress, improvement of mitochondrial function, and neuroprotective effects, aiming to provide a theoretical basis for future research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.